View NovoCure Ltd. NVCR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Fintel reports that Baillie Gifford & Co has filed a 13G/A form with the SEC disclosing ownership of 8,863,842 shares of Novocure Ltd (NVCR). This represents 8.45% of the company. In their previous ...

(Reuters) -Novocure Ltd's experimental device to treat a type of lung cancer helped in extending overall survival among patients in a late-stage study, but concerns around its commercial success sent ...

Earnings call Novocure delivered record net revenue of $655M in 2025, up 8% YoY, driven by strong international patient growth and new product launches. Management issued 2026 guidance of $675M-$705M ...

Investors in NovoCure Ltd (Symbol: NVCR) saw new options begin trading this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVCR ...

* NOVOCURE LTD - CONTINUING TO TREAT CURRENT CLINICAL TRIAL PATIENTS & ENROLL NEW PATIENTS AT EXISTING CLINICAL TRIAL SITES IN 6 ONGOING CLINICAL TRIALS * NOVOCURE LTD - COVID-19-RELATED EFFECTS ARE ...

Novocure Ltd (NASDAQ:NVCR) announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies ...

Novocure Ltd.’s stock soared 15% Wednesday after the company announced positive results from a late-stage trial of a medtech device to treat patients with lung cancer that has spread to their brains.

Operator: Good day, and thank you for standing by. Welcome to the NovoCure's Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. Operator: Good ...

Earnings call Novocure delivered record net revenue of $655M in 2025, up 8% YoY, driven by strong international patient growth and new product launches. Management issued 2026 guidance of $675M-$705M ...

Novocure's pancreatic cancer treatment meets main goal in late-stage study Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer ...

Visit a quote page and your recently viewed tickers will be displayed here. Jeryl Lynn Hilleman currently works at Omada Health, Inc., as Chairman, SI-BONE, Inc., as Independent Director from 2019, ...